US3653836A - Reagent for determining blood sugar - Google Patents

Reagent for determining blood sugar Download PDF

Info

Publication number
US3653836A
US3653836A US66953A US3653836DA US3653836A US 3653836 A US3653836 A US 3653836A US 66953 A US66953 A US 66953A US 3653836D A US3653836D A US 3653836DA US 3653836 A US3653836 A US 3653836A
Authority
US
United States
Prior art keywords
percent
weight
reagent
blood sugar
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US66953A
Inventor
Wolfgang Gruher
Erich Bernt
August Wilhelm Wahlefeld
Werner Dollacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US3653836A publication Critical patent/US3653836A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]
    • Y10T436/144444Glucose

Definitions

  • the present invention is concerned with a reagent for the determination of blood sugar by the o-toluidine method, which reagent does not contain glacial acetic acid.
  • isophthalic acid and terephthalic acid are useless for weight, based on total weight of composition.
  • the two above-mentioned glacial acetic acid-free reagents overcome the problem of malodor and also somewhat improve the sensitivity of the test.
  • This sensitivity is, in the case of the usual normal values for the blood sugar content in whole blood of 60 100 mg. percent, below the value ofE 0.100 at the measurement wavelength of 578 nm usually employed.
  • a further disadvantage of the two above-mentioned known reagents is the instability of the solvent mixture which is due to the content of readily volatile components.
  • the increased evaporation rate is of significance because the reagent must be heated for 8 minutes in a boiling waterbath for the development of the coloration.
  • the dissolved substances start to crystallize out.
  • phthalic acid is an outstanding catalyst for An especially preferred composition consists of 0.075 0.15 percent by weight thiourea, 20 25 percent by weight phthalic acid, 35 55 percent by weight dimethyl formamide, 20 40percent by weight ethylene glycol mono-lower alkyl ether and 7.5 10 percent by weight o-toluidine, based on total weight of composition.
  • lower alkly is to be understood to mean an alkyl radical containing up to six carbon atoms.
  • the reagent according to the present invention can contain up to about 5 percent water, without its usefulness being thereby impaired.
  • the reagent according to the present invention does not result in any unpleasant smell nor is there any danger of a loss of solvent when heating in order to bring about formation of the colored material.
  • the reagent is colorless to pale yellow in color and the viscosity is low so that there is no impairment of the pipetting due to air bubbles or after-runnings.
  • the reagent is also storage stable although, in the case of comparatively long periods of storage at an elevated temperature (33 C. an intensification of the yellow color can occur. However, this influences neither the measurement sensitivity to any considerable extent nor the stability of the color formed.
  • FIG. 1 is a plot extinction values against glucose concentration
  • the superior sensitivity of the reagent according to the present invention is of great practical importance since it is hereby possible, even in the cases of hypoglycaemia, as well as in the cases in which only very little blood is available, i.e., in the case of blood sugar measurement values of 30 50 mg. percent, to obtain extinctions of the order of 0.050 to 0.082 at 578 nm, measured against a blank, so that errors of measurement in the reading off of the photometer are very considerably reduced.
  • a further advantage of the reagent according to the present invention lies in the fact that in the region of the especially preferred composition, it represents a so-called optimum composition. This means that all individual components of the mixture are present in the concentration in which the sensitivity, the period of incubation of the test and the stability of the resultant color have their maxima and a slight alteration of the conditions does not cause any significant differences in the course of the test or in the measurement operation. The working errors are, therefore, in the case of this composition, extremely low.
  • the color which arises in the case of the o-toluidine reaction is, in principle, unstable. It is assumed that an unknown secondary reaction follows by means of which the extinction at 640 nm, the maximum, and at the measurement wavelength of 578 nm, decreases in the course of time. This instability of the color is reduced in the case of the reagent according to the had at ambient temperature at the end of the incubation.
  • glycollic acid reagent was used as comparison reagent.
  • superior stability of the reagent according to the present invention This improvement represents an important advantage when a large series of tests are to be measured one after the other.
  • a further advantage of the reagent according to the present invention lies in the fact that the stability is independent of the glucose concentration in the sample. The possibilities of error of the method are hereby minimized.
  • a further advantage of the reagent according to the present invention is its cheapness.
  • the cost of phthalic acid is only about one-ninth of the cost of glycollic acid.
  • Example 1 ml. ethylene glycol monoethyl ether were then added thereto and finally 18.0 ml. o-toluidine was stirred in.
  • 0.1 ml. of blood was pipetted into 1.0 ml. 3 percent trichloroacetic acid, mixed and, after standing for a few minutes, centrifuged.
  • Areagent composition for determination of blood sugar which composition comprises o-toluidine, thiourea, an ethylene glycol mono-lower alkyl ether, phthalic acid, and dimethyl formamide as a solubilizing agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A color-producing reagent for determining blood sugar comprising o-toluidine, thiourea, an ethylene glycol mono-lower alkyl ether, phthalic acid, and dimethyl formamide as a solubilizing agent, is outstandingly sensitive even to very low blood sugar contents, as in hypoglycaemia, and exhibits prolonged color stability.

Description

United States Patent Gruber et al.
[451 Apr. 4, 1972 REAGENT FOR DETERMINING BLOOD SUGAR Inventors: Wolfgang Gruher, Garatshausen nr. 16; Erich Bernt, 8000 Munich, Grunwalder Strasse 34; August Wilhelm Wahlefeld, Weilheim, Andreus-Schmidtner Strasse 20; Werner Doilacker, 8000 Munich, Schopenhege t 1.?" 9f Filed: Aug. 26, 1970 Appl. No.: 66,953
[30] Foreign Application Priority Data Aug. 27, 1969 Germany "P 19 43 580.4
US. Cl... ..23/230 B, 252/408 1m. Ci ..c01n 21/06, 00111 33/16 Field of Search ..23/23o B, 253 TP; 252/408 References Cited UNITED STATES PATENTS 3,453,180 7/1969 Fraser ..23/230 B OTHER PUBLICATIONS Chem. Abs. 67: 50965y (1967). Chem. Abs. 69: 93549y 1968). Chem. Abs. 69: l03698n 1968). Chem. Abs. 7i: I0133a(1969). Chem. Abs. 71: 278 172 (1969).
Primary Examiner-Morris O. Wolk Assistant Examiner-Sidney Marantz Attorney-Burgess, Dinklage & Sprung 57 ABSTRACT 7 Claims, 3 Drawing Figures REAGENT FOR DETERMINING BLOOD SUGAR The present invention is concerned with a reagent for the determination of blood sugar by the o-toluidine method, which reagent does not contain glacial acetic acid.
The determination of blood sugar with o-toluidine in glacial acetic acid is standard method in clinical laboratories. According to this method, the blood sample, after deproteinization, is mixed with about the tenfold amount of a reagent solution which contains o-toluidine and thiourea dissolved in glacial acetic acid. The mixture is heated, a green colored material being formed which is measured in a photometer at 630 nm.
This known method suffers from two important disadvantages which present considerable problems, especially in large laboratories in which routine analyses are carried out. On the one hand, the sensitivity is comparatively low, i.e., the possibility of error in the lower region of sensitivity is rather high. On the other hand, the use of glacial acetic acid as the the aldose-specific color reaction of o-toluidine, whereas, for
' example, isophthalic acid and terephthalic acid are useless for weight, based on total weight of composition.
reaction medium gives rise to a strong and very unpleasant smell, not only when pipetting the reagents but also when heating the samples in a boiling waterbath, as well as when cleaning the glass reaction vessels used. Furthermore, the corrosion of the photometer by the glacial acetic acid vapors is increased considerably.
Attempts have, therefore, already been made to overcome these disadvantages by the use of another solvent and reaction medium. Thus, it has already been proposed to use semi-con centrated acetic acid. However, this does not result in the disadvantages being overcome.
it has been proposed by A. Hartel et al (2. klin. Chem. u. klin, Biochem., 7, 14/1969) to replace the glacial acetic acid with a mixture of glycollic acid and malic acid, water, methanol and ethylene glycol monomethyl ether. A reagent of this type is also commercially available.
In the case of another commercially available reagent, the glacial acetic acid is' replaced with organic esters and salicylic acid.
The two above-mentioned glacial acetic acid-free reagents overcome the problem of malodor and also somewhat improve the sensitivity of the test. This sensitivity is, in the case of the usual normal values for the blood sugar content in whole blood of 60 100 mg. percent, below the value ofE 0.100 at the measurement wavelength of 578 nm usually employed.
However, in the case of very low blood sugar values, such as occur in the cases of hypoglycaemia, the extinction differences are of the order of the blank. Therefore, there is a need for the provision of a reagent which still further increases the sensitivity of the method.
A further disadvantage of the two above-mentioned known reagents is the instability of the solvent mixture which is due to the content of readily volatile components. The increased evaporation rate is of significance because the reagent must be heated for 8 minutes in a boiling waterbath for the development of the coloration. In the case of the known salicylic acidcontaining reagent, even after standing for about 1 hour in the air, the dissolved substances start to crystallize out.
Finally, another disadvantage is that the substances used instead of glacial acetic acid are considerably more expensive and thus the economic competitiveness of such reagents is impaired.
It is, therefore, an object of the present invention to provide a new reagent for the determination of blood sugar which avoids the above-mentioned disadvantages of the known reagents and is dependable, very sensitive and economical. v
The reagent according to the present invention for the determination of blood sugar contains o-toluidine, thiourea, an ethylene glycol mono-lower alkyl ether, and an acid and is characterized in that it contains phthalic acid as the acid and dimethyl formamide as a solubilizing agent.
From A. Haertel and H. Lang (Arztl. Lab., 15, 60/1966), it was known that non-hydroxylated dicarboxylic acids could not replace the glacial acetic acid because they prevented the formation of the desired colored material. It is, therefore, most surprising that phthalic acid is an outstanding catalyst for An especially preferred composition consists of 0.075 0.15 percent by weight thiourea, 20 25 percent by weight phthalic acid, 35 55 percent by weight dimethyl formamide, 20 40percent by weight ethylene glycol mono-lower alkyl ether and 7.5 10 percent by weight o-toluidine, based on total weight of composition.
Within the scope of the present invention, the term "lower alkly is to be understood to mean an alkyl radical containing up to six carbon atoms.
The reagent according to the present invention can contain up to about 5 percent water, without its usefulness being thereby impaired.
The reagent according to the present invention does not result in any unpleasant smell nor is there any danger of a loss of solvent when heating in order to bring about formation of the colored material. The reagent is colorless to pale yellow in color and the viscosity is low so that there is no impairment of the pipetting due to air bubbles or after-runnings. The afterrunnings in the case of a normal pipetting amount to 5 l percent, i.e., in the case of 2.0 ml. of reagent, are 0.02 ml. The reagent is also storage stable although, in the case of comparatively long periods of storage at an elevated temperature (33 C. an intensification of the yellow color can occur. However, this influences neither the measurement sensitivity to any considerable extent nor the stability of the color formed.
An especial advantage of the reagent according to the present invention is its outstanding sensitivity, even in the case of low glucose contents. Thus, even in the case of the range of 20 400 mg. percent (and even up to l g. percent) glucose content, there is obtained a very good linear proportionality between the extinction values at 578 nm and the glucose concentration. in this regard, reference is made to the accompanying drawings in which:
FIG. 1 is a plot extinction values against glucose concentration;
FIG. 2 is a plot of color intensity of an incubated test sample TABLE 1 Comparison of the Sensitivity of Various Blood Sugar Determination Methods Sensitivity-200 mg% glucose Sensitivity sra m in referred Reagent blank sample E to (i) (I) o-toluidine method with glacial acetic acid (2) o-toluidine 0.080 0.285 0.205 175.5% method without glacial acetic acid but with glycollic acid (3) o-toluidine 0.054 0.326 0.272 232% method without glacial acetic acid but with salicylic acid (4) reagent 0.049 0.382 0.333 285% mixture according to the invention of otoluidine and phthalic acid ratio of(4):(2)= 1.62: [.0
The superior sensitivity of the reagent according to the present invention, which can be seen from the last column of the above Table l, is of great practical importance since it is hereby possible, even in the cases of hypoglycaemia, as well as in the cases in which only very little blood is available, i.e., in the case of blood sugar measurement values of 30 50 mg. percent, to obtain extinctions of the order of 0.050 to 0.082 at 578 nm, measured against a blank, so that errors of measurement in the reading off of the photometer are very considerably reduced.
A further advantage of the reagent according to the present invention lies in the fact that in the region of the especially preferred composition, it represents a so-called optimum composition. This means that all individual components of the mixture are present in the concentration in which the sensitivity, the period of incubation of the test and the stability of the resultant color have their maxima and a slight alteration of the conditions does not cause any significant differences in the course of the test or in the measurement operation. The working errors are, therefore, in the case of this composition, extremely low.
The color which arises in the case of the o-toluidine reaction is, in principle, unstable. It is assumed that an unknown secondary reaction follows by means of which the extinction at 640 nm, the maximum, and at the measurement wavelength of 578 nm, decreases in the course of time. This instability of the color is reduced in the case of the reagent according to the had at ambient temperature at the end of the incubation. The
glycollic acid reagent was used as comparison reagent. There can clearly be appreciated the superior stability of the reagent according to the present invention. This improvement represents an important advantage when a large series of tests are to be measured one after the other.
A further advantage of the reagent according to the present invention lies in the fact that the stability is independent of the glucose concentration in the sample. The possibilities of error of the method are hereby minimized.
A further advantage of the reagent according to the present invention is its cheapness. Thus, the cost of phthalic acid is only about one-ninth of the cost of glycollic acid.
The following Examples are given for the purpose of illustrating the present invention:
Example 1 ml. ethylene glycol monoethyl ether were then added thereto and finally 18.0 ml. o-toluidine was stirred in.
For the purpose of deproteinization, 0.1 ml. of blood was pipetted into 1.0 ml. 3 percent trichloroacetic acid, mixed and, after standing for a few minutes, centrifuged.
From the supernatant, there was taken 0.2 ml. and this was mixed with 2.0 ml. of the above-described reagent according to the present invention. The mixture of supernatant and reagent was heated for 8 minutes on a boiling waterbath. After cooling in cold water, the resultant green colored material was measured in a photometer at 578 nm against a blank (trichloroacetic acid and reagent). A glucose standard mg. glucose/I00 ml. 0.2 percent benzoic acid solution) was treated in the same manner. The blood sugar content was calculated from the following equation:
sample X The determination was repeated with a series of blood samples of differing glucose content. The results obtained are set out in FIG. 1 of the accompanying drawings. They show the outstanding linear proportionality of the results which are obtained with the reagent according to the present invention.
In the above-described manner, the standard deviation of the determined blood sugar values from one another was ascertained by means of 10 determinations on the same serum. The standard deviation, which serves for the assessment of the distribution of the individual values around the arithmetic mean, was calculated from the following equation:
In the present case, s i: 1.25 mg. percent. As arithmetic mean value (Y) in the case of the 10 determinations, there was found 163.3 mg. percent glucose. The exactitude which can be achieved with the reagent according to the present invention can also be expressed by the following equation:
Y: 1 s= 1.63.31- 1.25 mg. percent The variation coefiicient VC), which is an expression of the standard deviation in percent of the mean value, amounted to i 0.76 percent, calculated from the following equation:
sXlOO Example 2 The o-toluidine method, with the use of the reagent according to. the present invention, was compared with the known enzymatic, highly specific blood sugar determination method, using the system hexokinase/intermediate enzyme. In this case, 25 different whole blood samples were tested in the manner described in Example 1. The same number of blood samples were determined enzymatically with hexokinase/intermediate enzyme. The blood sugar values obtained by both methods were compared. The results obtained are shown in FIG. 3 of the accompanying drawings. The good agreement of the values which were obtained by the two methods was obvious. The distribution of the comparable individual values was, on the average, 1 2.0 percent.
What is claimed is:
1. Areagent composition for determination of blood sugar which composition comprises o-toluidine, thiourea, an ethylene glycol mono-lower alkyl ether, phthalic acid, and dimethyl formamide as a solubilizing agent.
2. A reagent composition as claimed in claim 1 in which water is contained in an amount of up to 5 percent by volume.
3. Method for the determination of blood sugar which comprises mixing a blood sample with a reagent composition as claimed in claim 1 and measuring the resulting mixture photometrically'as an indication of the'blood sugar content.
4. A reagent composition as claimed in claim 1 which comprises 0.05 2.5 percent by weight thiourea, 5 33 percent by weight phthalic acid, 25 65 percent by weight dimethyl formamide, l0 50 percent by weight ethylene glycol monolower alkyl ether and 2.5 percent by weight o-toluidine, based on total weight of composition.
5. A reagent composition as claimed in claim 4 which comprises 0.075 0.15 percent by weight thiourea, percent by weight phthalic acid, 35 55 percent by weight dimethyl-formamide, 2O 40 percent by weight ethylene glycol mono-lower alkyl ether and 7.5 10 percent by weight o-toluidine, based on total weight of composition.
6. A reagent composition as claimed in claim 4 wherein the total volume of dimethyl formamide and of alkylene glycol mono-lower alkyl ether does not exceed parts by volume.
7 Method for the determination of blood sugar which comprises mixing a blood sample with a reagent composition as claimed in claim 4 and measuring the resulting mixture photometrically as an indication of the blood sugar content.
* Il l

Claims (5)

  1. 2. A reagent composition as claimed in claim 1 in which water is contained in an Amount of up to 5 percent by volume.
  2. 3. Method for the determination of blood sugar which comprises mixing a blood sample with a reagent composition as claimed in claim 1 and measuring the resulting mixture photometrically as an indication of the blood sugar content.
  3. 4. A reagent composition as claimed in claim 1 which comprises 0.05 - 2.5 percent by weight thiourea, 5 - 33 percent by weight phthalic acid, 25 - 65 percent by weight dimethyl formamide, 10 -50 percent by weight ethylene glycol mono-lower alkyl ether and 2.5 - 15 percent by weight o-toluidine, based on total weight of composition.
  4. 5. A reagent composition as claimed in claim 4 which comprises 0.075 - 0.15 percent by weight thiourea, 20 - 25 percent by weight phthalic acid, 35 - 55 percent by weight dimethyl-formamide, 20 - 40 percent by weight ethylene glycol mono-lower alkyl ether and 7.5 - 10 percent by weight o-toluidine, based on total weight of composition.
  5. 6. A reagent composition as claimed in claim 4 wherein the total volume of dimethyl formamide and of alkylene glycol mono-lower alkyl ether does not exceed 150 parts by volume. 7 Method for the determination of blood sugar which comprises mixing a blood sample with a reagent composition as claimed in claim 4 and measuring the resulting mixture photometrically as an indication of the blood sugar content.
US66953A 1969-08-27 1970-08-26 Reagent for determining blood sugar Expired - Lifetime US3653836A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19691943580 DE1943580B2 (en) 1969-08-27 1969-08-27 BLOOD GLUCOSE DETECTION REAGENTS

Publications (1)

Publication Number Publication Date
US3653836A true US3653836A (en) 1972-04-04

Family

ID=5743926

Family Applications (1)

Application Number Title Priority Date Filing Date
US66953A Expired - Lifetime US3653836A (en) 1969-08-27 1970-08-26 Reagent for determining blood sugar

Country Status (11)

Country Link
US (1) US3653836A (en)
JP (1) JPS494356B1 (en)
BR (1) BR7020400D0 (en)
CH (1) CH538118A (en)
DE (1) DE1943580B2 (en)
FR (1) FR2059346A5 (en)
GB (1) GB1261477A (en)
IL (1) IL34773A (en)
NL (1) NL7011423A (en)
SE (1) SE360176B (en)
ZA (1) ZA705187B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853469A (en) * 1972-08-30 1974-12-10 Medico Electronic Inc Reagent and method for phosphorus determination
US3853473A (en) * 1972-08-30 1974-12-10 Medico Electronic Inc Reagent and method for urea determination
WO1986003585A1 (en) * 1984-12-11 1986-06-19 Lawrence Paul J Fecal occult blood test reagents and methods
US4818702A (en) * 1986-06-02 1989-04-04 Litmus Concepts, Inc. Fecal occult blood test reagent
US5426032A (en) * 1986-08-13 1995-06-20 Lifescan, Inc. No-wipe whole blood glucose test strip
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1098808A (en) * 1977-03-14 1981-04-07 Charles T. W. Lam Test composition and device for determining peroxidatively active substances

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453180A (en) * 1965-08-02 1969-07-01 Miles Lab Test article

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453180A (en) * 1965-08-02 1969-07-01 Miles Lab Test article

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chem. Abs. 67: 50965y (1967). *
Chem. Abs. 69: 103698n (1968). *
Chem. Abs. 69: 93549y (1968). *
Chem. Abs. 71: 10133a (1969). *
Chem. Abs. 71: 27817z (1969). *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853469A (en) * 1972-08-30 1974-12-10 Medico Electronic Inc Reagent and method for phosphorus determination
US3853473A (en) * 1972-08-30 1974-12-10 Medico Electronic Inc Reagent and method for urea determination
WO1986003585A1 (en) * 1984-12-11 1986-06-19 Lawrence Paul J Fecal occult blood test reagents and methods
US4818702A (en) * 1986-06-02 1989-04-04 Litmus Concepts, Inc. Fecal occult blood test reagent
US20030054427A1 (en) * 1986-08-13 2003-03-20 Roger Phillips Minimum procedure system for the determination of analytes
US6858401B2 (en) 1986-08-13 2005-02-22 Lifescan, Inc. Minimum procedure system for the determination of analytes
US5843692A (en) * 1986-08-13 1998-12-01 Lifescan, Inc. Automatic initiation of a time interval for measuring glucose concentration in a sample of whole blood
US6268162B1 (en) 1986-08-13 2001-07-31 Lifescan, Inc. Reflectance measurement of analyte concentration with automatic initiation of timing
US6887426B2 (en) 1986-08-13 2005-05-03 Roger Phillips Reagents test strip adapted for receiving an unmeasured sample while in use in an apparatus
US6881550B2 (en) 1986-08-13 2005-04-19 Roger Phillips Method for the determination of glucose employing an apparatus emplaced matrix
US5426032A (en) * 1986-08-13 1995-06-20 Lifescan, Inc. No-wipe whole blood glucose test strip
US5563042A (en) * 1986-08-13 1996-10-08 Lifescan, Inc. Whole blood glucose test strip
US20030073153A1 (en) * 1986-08-13 2003-04-17 Roger Phillips Minimum procedure system for the determination of analytes
US20030073151A1 (en) * 1986-08-13 2003-04-17 Roger Phillips Minimum procedure system
US20030073152A1 (en) * 1986-08-13 2003-04-17 Roger Phillips Minimum procedure system for the determination of analytes
US6821483B2 (en) 1986-08-13 2004-11-23 Lifescan, Inc. Reagents test strip with alignment notch
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US6979571B2 (en) 1999-11-24 2005-12-27 Home Diagnostics, Inc. Method of using a protective test strip platform for optical meter apparatus
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
US7390665B2 (en) 2001-02-28 2008-06-24 Gilmour Steven B Distinguishing test types through spectral analysis

Also Published As

Publication number Publication date
IL34773A (en) 1973-05-31
DE1943580B2 (en) 1971-08-05
BR7020400D0 (en) 1973-03-20
GB1261477A (en) 1972-01-26
DE1943580A1 (en) 1971-04-08
ZA705187B (en) 1971-05-27
NL7011423A (en) 1971-03-02
FR2059346A5 (en) 1971-05-28
IL34773A0 (en) 1970-08-19
CH538118A (en) 1973-06-15
SE360176B (en) 1973-09-17
JPS494356B1 (en) 1974-01-31

Similar Documents

Publication Publication Date Title
Dorsey et al. A heated biuret-Folin protein assay which gives equal absorbance with different proteins
Watson A simple method for the determination of serum cholesterol
Lowry [17] Micromethods for the assay of enzymes
Nelson A photometric adaptation of the Somogyi method for the determination of glucose
Werner et al. Ultramicro determination of serum triglycerides by bioluminescent assay.
US5776719A (en) Diagnostic compositions and devices utilizing same
EP0102504B1 (en) Ascorbate-resistant broad range glucose test composition, test device and method
US3653836A (en) Reagent for determining blood sugar
US4212938A (en) Reagent and method for the determination of cholesterol
US3595755A (en) Detection of hydrogen peroxide
US4897346A (en) Stabilized liquid enzyme composition for glucose determination
JP3131924B2 (en) Improved methods and reagents for analyte measurement
US4143080A (en) Method and reagent for the assay of hydroperoxide
US4414326A (en) Diagnostic agents
US3862012A (en) Quantitative determination of uric acid
Slater [3] Manometric methods and phosphate determination
Momose et al. Determination of Total Cholesterol in Blood Serum with Perchloric Acid-Phosphoric Acid-Ferric Chloride Reagent.
JPS59183698A (en) Quantitative determination of substrate
ES2227796T3 (en) METHODS AND REAGENTS FOR DETERMINING QUANTITATIVELY ASCORBIC ACID.
EP0044432B1 (en) Stabilized enzymatic solutions and method for determining total cholesterol in human serum
Asp Improved method for the assay of phenylglycosidase activity with a 4-aminoantipyrine reagent
US3778384A (en) Diagnostic composition for the quantitative determination of glucose
EP0586397A4 (en) Improved method and reagent for determination of an analyte.
US3558516A (en) Cholesterol determination reagent of ferric perchlorate,sulfuric acid and ethyl acetate
US4142938A (en) Determination of triglycerides and glycerol